

Lexaria Bioscience Corp.

10:39 19 Mar 2020

Lexaria Bioscience initiates coronavirus drug delivery program

Lexaria Bioscience Corp (OTCMKTS:LXRP) (CSE:LXX), a specialist in drug delivery technology, revealed Thursday that it has initiated a program with top labs in the United States and Canada to study the benefits of the company's DehydraTECH drug delivery platform for boosting the delivery and effectiveness of certain antiretroviral drugs being tapped in the fight against the coronavirus (COVID-19).

Researchers are currently investigating different antiretroviral drugs as potential candidates to combat the disease.

"Many of these are fat-soluble and present significant bioavailability challenges in successfully reaching the human bloodstream when administered in oral form," the Kelowna, British Columbia-based company — which is an established leader in oral delivery of fat-soluble drugs — noted in a statement.

According to a medical journal, Lexaria's patented DehydraTECH technology delivers fat-soluble drugs with increases of up to 317% more drug quantified in the blood in a human clinical study within the first 30 minutes of dosing relative to concentration matched controls.

READ: Lexaria Bioscience produces first DehydraTECH-enabled CBD emulsion for licensed client

If DehydraTECH shows similar performance improvements in the drug delivery characteristics of antiviral drugs, it could be used to more effectively treat coronavirus patients, the company said.

As a first step in the research program, Lexaria intends to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers of three antiretroviral drugs that have previously been studied against other coronavirus strains, comparing DehydraTECH formulations to controls without Lexaria's technology.

Lexaria intends to conduct the study at a leading Canadian University where a study design and plan have already been submitted for ethics board approval.

Additional research may include "expanded pharmacokinetic and pharmacodynamic screening," including studies in appropriate "coronavirus animal models for efficacy evaluation," it added.

Lexaria believes DehydraTECH may prove useful in fighting coronavirus and has held discussions with labs that may be able to expand the number of prospective drugs using DehydraTECH under evaluation for coronavirus applications.

Pending positive outcomes from its planned research activities, Lexaria said it will "aggressively engage with prospective strategic partners to improve drug development" as a drug delivery technology licensor and provider.

Price: 0.39

Market Cap: \$34.94 m

1 Year Share Price Graph



Share Information

Code: LXX

Listing: CSE

52 week	High	Low
	1.27	0.31

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

action@proactiveinvestors.com

DehydraTECH is able to mask unwanted tastes, improve onset speed and increase the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

The company's patented technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion, lower overall dosing and higher effectiveness for lipophilic active molecules. Lexaria is also developing DehydraTECH for nicotine and painkillers called nonsteroidal anti-inflammatory drugs, or NSAIDs for short.

Shares in New York surged over 31% to US\$0.32.

---Updates for share price---

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).